These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 27892978)

  • 1. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors.
    Sperduto PW; De B; Li J; Carpenter D; Kirkpatrick J; Milligan M; Shih HA; Kutuk T; Kotecha R; Higaki H; Otsuka M; Aoyama H; Bourgoin M; Roberge D; Dajani S; Sachdev S; Gainey J; Buatti JM; Breen W; Brown PD; Ni L; Braunstein S; Gallitto M; Wang TJC; Shanley R; Lou E; Shiao J; Gaspar LE; Tanabe S; Nakano T; An Y; Chiang V; Zeng L; Soliman H; Elhalawani H; Cagney D; Thomas E; Boggs DH; Ahluwalia MS; Mehta MP
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):60-74. PubMed ID: 35331827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Applicability of the adjusted graded prognostic assessment for lung cancer with brain metastases using molecular markers (Lung-molGPA) in a Chinese cohort: A retrospective study of multiple institutions.
    Zhang T; Zhang Y; Zhou L; Deng S; Huang M; Liu Y; Liu Y; Gong Y; Zhu J; Xue J; Bai Y; Ma H; Zhang Y; Yu M; Li Y; Wang Y; Zou B; Zhou X; Xiu W; Na F; Xu Y; Peng F; Wang J; Lu Y
    Cancer Med; 2020 Dec; 9(23):8772-8781. PubMed ID: 33027555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
    Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):812-816. PubMed ID: 29063850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Chen K; Yu X; Zhang F; Xu Y; Zhang P; Huang Z; Fan Y
    Lung Cancer; 2018 Nov; 125():8-13. PubMed ID: 30429042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer.
    Crouzen JA; Mast ME; Hakstege M; Broekman MLD; Baladi C; Mertens BJA; Nandoe Tewarie RDS; Kerkhof M; Vos MJ; Maas KW; Souwer ETD; Wiggenraad RGJ; van der Voort van Zyp NCMG; Kiderlen M; Petoukhova AL; Zindler JD
    Radiother Oncol; 2024 Sep; 198():110405. PubMed ID: 38925263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
    Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
    Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA).
    Nieder C; Hintz M; Oehlke O; Bilger A; Grosu AL
    Radiat Oncol; 2017 Jun; 12(1):107. PubMed ID: 28651600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.
    Yin K; Li YS; Zheng MM; Jiang BY; Li WF; Yang JJ; Tu HY; Zhou Q; Zhong WZ; Yang XN; Chen HJ; Yan HH; Li LL; Wu YL; Zhang XC
    Lung Cancer; 2019 May; 131():134-138. PubMed ID: 31027690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool.
    Sperduto PW; Deegan BJ; Li J; Jethwa KR; Brown PD; Lockney N; Beal K; Rana NG; Attia A; Tseng CL; Sahgal A; Shanley R; Sperduto WA; Lou E; Zahra A; Buatti JM; Yu JB; Chiang V; Molitoris JK; Masucci L; Roberge D; Shi DD; Shih HA; Olson A; Kirkpatrick JP; Braunstein S; Sneed P; Mehta MP
    Neuro Oncol; 2018 Nov; 20(12):1652-1660. PubMed ID: 30418657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applicability of graded prognostic assessment of lung cancer using molecular markers to lung adenocarcinoma patients with brain metastases.
    Li H; Lian J; Han S; Wang W; Jia H; Cao J; Zhang X; Song X; Jia S; Ren J; Yang W; Xi Y; Lan S
    Oncotarget; 2017 Sep; 8(41):70727-70735. PubMed ID: 29050314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Disease-Specific GPA for Patients With 1 to 3 Synchronous Brain Metastases in Newly Diagnosed NSCLC.
    Woody NM; Greer MD; Reddy CA; Videtic GMM; Chao ST; Murphy ES; Suh JH; Angelov L; Barnett GH; Vogelbaum MA; Stephans KL
    Clin Lung Cancer; 2018 Jan; 19(1):e141-e147. PubMed ID: 28739316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain metastases in Japanese NSCLC patients: prognostic assessment and the use of osimertinib and immune checkpoint inhibitors-retrospective study.
    Higaki H; Nishioka K; Otsuka M; Nishikawa N; Shido M; Minatogawa H; Nishikawa Y; Takashina R; Hashimoto T; Katoh N; Taguchi H; Kinoshita R; Yasuda K; Mori T; Uchinami Y; Koizumi F; Fujita Y; Takahashi S; Hattori T; Nishiyama N; Aoyama H
    Radiat Oncol; 2023 Feb; 18(1):25. PubMed ID: 36750899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.
    Sperduto PW; Chao ST; Sneed PK; Luo X; Suh J; Roberge D; Bhatt A; Jensen AW; Brown PD; Shih H; Kirkpatrick J; Schwer A; Gaspar LE; Fiveash JB; Chiang V; Knisely J; Sperduto CM; Mehta M
    Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):655-61. PubMed ID: 19942357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
    Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
    J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
    Aoyama H; Tago M; Shirato H;
    JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic indices in stereotactic radiotherapy of brain metastases of non-small cell lung cancer.
    Kaul D; Angelidis A; Budach V; Ghadjar P; Kufeld M; Badakhshi H
    Radiat Oncol; 2015 Nov; 10():244. PubMed ID: 26611493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab improved prognosis for advanced EGFR-mutant lung adenocarcinoma with brain metastasis receiving cerebral radiotherapy.
    Zhou Y; Li J; Li Y; Deng G; Wang Q; Qin H; Li J; Li Z
    Clin Transl Oncol; 2024 Aug; 26(8):1968-1975. PubMed ID: 38478262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today.
    Sperduto PW; Mesko S; Li J; Cagney D; Aizer A; Lin NU; Nesbit E; Kruser TJ; Chan J; Braunstein S; Lee J; Kirkpatrick JP; Breen W; Brown PD; Shi D; Shih HA; Soliman H; Sahgal A; Shanley R; Sperduto W; Lou E; Everett A; Boggs DH; Masucci L; Roberge D; Remick J; Plichta K; Buatti JM; Jain S; Gaspar LE; Wu CC; Wang TJC; Bryant J; Chuong M; Yu J; Chiang V; Nakano T; Aoyama H; Mehta MP
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):334-343. PubMed ID: 32084525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.
    Churilla TM; Ballman KV; Brown PD; Twohy EL; Jaeckle K; Farace E; Cerhan JH; Anderson SK; Carrero XW; Garces YI; Barker FG; Deming R; Dixon JG; Burri SH; Chung C; Ménard C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1173-1178. PubMed ID: 28939223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.